Getting your ADCs to the clinic: Considerations for early stage development
Seminar - London, United Kingdom
The development of existing or novel monoclonal antibodies as drug-conjugates to increase the targeted clinical effect of these proteins has rapidly increased in recent years.
SMi's masterclass hosted by PAREXEL International will discuss ADCs which are being tested in the clinic in a range of oncology indications. In the absence of specific guidance on the development of ADCs, this workshop aims to help participants understand the CMC issues during the development, with a particular focus on the assessment and control of the quality of such products.
Benefits of Attending
• Identify key parameters for non-clinical studies to support a Phase 1 clinical trial
• Consider the factors that influence the choice of conjugate and linker types
• Learn how to create an early phase product development plan that meets regulatory expectations
• Network with and learn from senior industry representatives
Organization: SMi Group
(Courtesy of Getting your ADCs to the clinic: Considerations for early stage development Seminar's logo, via skiddle.com)
Getting your ADCs to the clinic: Considerations for early stage development
Mon, Dec 02, 2013 - Mon, Dec 02, 2013
Holiday Inn Bloomsbury,
Coram Street, London, United Kingdom
If you'd like to ask a question or post a comment about this talk please do so below.
This seminar posting is brought to you by Biotechnology Calendar, Inc. providing access to research information and research tools for nearly 20 years. Visit our Science Market Update Blog for current science funding and market information or see our schedule of upcoming science research laboratory product shows.
